1. Antimicrobial use in US hospitals: comparison of results from emerging infections program prevalence surveys, 2015 and 2011;Magill;Clin Infect Dis,2020
2. Trends in U.S. Burden of Clostridioides difficile infection and outcomes;Guh;New Engl J Med,2020
3. Daniau C, Leon L, Berger-Carbonne A. Enquête nationale de prévalence des infections nosocomiales et des traitements anti-infectieux en établissements de santé, mai–juin 2017–2019. https://www.santepubliquefrance.fr/maladies-et-traumatismes/infections-associees-aux-soins-et-resistance-aux-antibiotiques/infections-associees-aux-soins/documents/enquetes-etudes/enquete-nationale-de-prevalence-des-infections-nosocomiales-et-des-traitements-anti-infectieux-en-etablissements-de-sante-mai-juin-2017 (accessed 2019).
4. Swissnoso. Point Prevalence Survey 2017 of healthcare-associated infections and antimicrobial use in Swiss acute care hospitals 2018. https://www.swissnoso.ch/fileadmin/swissnoso/Dokumente/5_Forschung_und_Entwicklung/2_Punktpraevalenzstudie/ch_pps_2017_report_FINAL2.pdf) (accessed January 22, 2018).
5. Multicenter prevalence study comparing molecular and toxin assays for Clostridioides difficile surveillance, Switzerland;Widmer;Emerg Infect Dis,2020